HDACs can regulate oncogene and tumor suppressor gene activities, which thereby play a vital part in tumorigenesis.29 HDACs are usually investigated in the preclinical studies on hematological malignancies and solid tumors such as the IM-resistant CML.29,30 In the current work, CAY10683, the new selective HDAC2 inhibitor, was utilized in combination with IM for treating hematological disorders for the first time. Here, HDAC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.